FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085339741> ?p ?o ?g. }

• W2085339741 endingPage "444" @default.
• W2085339741 startingPage "440" @default.
• W2085339741 abstract "OBJECTIVES This study assessed the role of angiotensin II type 1 (AT1) receptor antagonists on inflammatory mechanisms involved in atherogenesis. Specific inflammatory markers included solubilized tumor necrosis factor-alpha receptor II (sTNF-αRII), vascular cell adhesion molecule-1 (VCAM-1) and superoxide. In addition, the AT1receptor blocker irbesartan was evaluated for its ability to suppress these markers in individuals with atherosclerosis. BACKGROUND Mechanisms involved in the complex process of atherogenesis include alterations in the inflammatory responses. The use of compounds that suppress these responses may reduce the degree of damage seen in atherosclerosis. METHODS With a cross-sectional study design, 33 normotensive patients with stable coronary artery disease (CAD) were treated with irbesartan for a 24-week period. These patients were compared against a control population with no known coronary atherosclerosis. Marker levels were measured by enzyme-linked immunosorbent assay technique and lucigenin chemiluminescence assay and statistically evaluated by two-way repeated measures analysis of variance. RESULTS All patients with coronary artery disease had increased levels of inflammatory molecules over those of control patients. Treatment with irbesartan in these patients significantly reduced levels of inflammatory molecules measured. Soluble VCAM-1 levels were reduced by 36%; soluble TNF-alpha levels were reduced by 54% and superoxide level decreased by 52%. Maximal suppression of inflammatory markers by irbesartan therapy in patients with CAD was seen at 12 weeks. CONCLUSIONS The effect of irbesartan on each inflammatory marker is significant. Our results show that use of irbesartan may retard the inflammatory process seen in premature forms of atherosclerosis." @default.
• W2085339741 created "2016-06-24" @default.
• W2085339741 creator A5018346155 @default.
• W2085339741 creator A5047111748 @default.
• W2085339741 creator A5072990052 @default.
• W2085339741 creator A5076488599 @default.
• W2085339741 date "2001-02-01" @default.
• W2085339741 modified "2023-10-06" @default.
• W2085339741 title "Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis" @default.
• W2085339741 cites W1602123692 @default.
• W2085339741 cites W1971463556 @default.
• W2085339741 cites W1973601126 @default.
• W2085339741 cites W1985832424 @default.
• W2085339741 cites W2013286419 @default.
• W2085339741 cites W2017800047 @default.
• W2085339741 cites W2021193012 @default.
• W2085339741 cites W2023842550 @default.
• W2085339741 cites W2041083253 @default.
• W2085339741 cites W2043700823 @default.
• W2085339741 cites W2061710689 @default.
• W2085339741 cites W2082921744 @default.
• W2085339741 cites W2103139383 @default.
• W2085339741 cites W2110182057 @default.
• W2085339741 cites W2137570167 @default.
• W2085339741 cites W2141443485 @default.
• W2085339741 cites W2156461484 @default.
• W2085339741 cites W2167866149 @default.
• W2085339741 cites W2208872067 @default.
• W2085339741 cites W2325043984 @default.
• W2085339741 cites W2410133262 @default.
• W2085339741 cites W2413426335 @default.
• W2085339741 cites W350571946 @default.
• W2085339741 cites W4323238732 @default.
• W2085339741 doi "https://doi.org/10.1016/s0735-1097(00)01138-4" @default.
• W2085339741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11216960" @default.
• W2085339741 hasPublicationYear "2001" @default.
• W2085339741 type Work @default.
• W2085339741 sameAs 2085339741 @default.
• W2085339741 citedByCount "164" @default.
• W2085339741 countsByYear W20853397412012 @default.
• W2085339741 countsByYear W20853397412013 @default.
• W2085339741 countsByYear W20853397412014 @default.
• W2085339741 countsByYear W20853397412015 @default.
• W2085339741 countsByYear W20853397412016 @default.
• W2085339741 countsByYear W20853397412017 @default.
• W2085339741 countsByYear W20853397412018 @default.
• W2085339741 countsByYear W20853397412019 @default.
• W2085339741 countsByYear W20853397412020 @default.
• W2085339741 countsByYear W20853397412021 @default.
• W2085339741 countsByYear W20853397412022 @default.
• W2085339741 crossrefType "journal-article" @default.
• W2085339741 hasAuthorship W2085339741A5018346155 @default.
• W2085339741 hasAuthorship W2085339741A5047111748 @default.
• W2085339741 hasAuthorship W2085339741A5072990052 @default.
• W2085339741 hasAuthorship W2085339741A5076488599 @default.
• W2085339741 hasBestOaLocation W20853397411 @default.
• W2085339741 hasConcept C123915805 @default.
• W2085339741 hasConcept C126322002 @default.
• W2085339741 hasConcept C134018914 @default.
• W2085339741 hasConcept C170493617 @default.
• W2085339741 hasConcept C203014093 @default.
• W2085339741 hasConcept C2776914184 @default.
• W2085339741 hasConcept C2778213512 @default.
• W2085339741 hasConcept C2780259554 @default.
• W2085339741 hasConcept C2908647359 @default.
• W2085339741 hasConcept C2908929049 @default.
• W2085339741 hasConcept C71924100 @default.
• W2085339741 hasConcept C84393581 @default.
• W2085339741 hasConcept C98274493 @default.
• W2085339741 hasConcept C99454951 @default.
• W2085339741 hasConceptScore W2085339741C123915805 @default.
• W2085339741 hasConceptScore W2085339741C126322002 @default.
• W2085339741 hasConceptScore W2085339741C134018914 @default.
• W2085339741 hasConceptScore W2085339741C170493617 @default.
• W2085339741 hasConceptScore W2085339741C203014093 @default.
• W2085339741 hasConceptScore W2085339741C2776914184 @default.
• W2085339741 hasConceptScore W2085339741C2778213512 @default.
• W2085339741 hasConceptScore W2085339741C2780259554 @default.
• W2085339741 hasConceptScore W2085339741C2908647359 @default.
• W2085339741 hasConceptScore W2085339741C2908929049 @default.
• W2085339741 hasConceptScore W2085339741C71924100 @default.
• W2085339741 hasConceptScore W2085339741C84393581 @default.
• W2085339741 hasConceptScore W2085339741C98274493 @default.
• W2085339741 hasConceptScore W2085339741C99454951 @default.
• W2085339741 hasIssue "2" @default.
• W2085339741 hasLocation W20853397411 @default.
• W2085339741 hasLocation W20853397412 @default.
• W2085339741 hasOpenAccess W2085339741 @default.
• W2085339741 hasPrimaryLocation W20853397411 @default.
• W2085339741 hasRelatedWork W1974641745 @default.
• W2085339741 hasRelatedWork W2024736606 @default.
• W2085339741 hasRelatedWork W2048334412 @default.
• W2085339741 hasRelatedWork W2063619316 @default.
• W2085339741 hasRelatedWork W2069855804 @default.
• W2085339741 hasRelatedWork W2101909726 @default.
• W2085339741 hasRelatedWork W2116796027 @default.
• W2085339741 hasRelatedWork W2151139437 @default.
• W2085339741 hasRelatedWork W2334147949 @default.

• next